The University of Oxford in the United Kingdom launched a trial on humans last week to develop the world’s fastest vaccine against the new novel Corona vaccine.
But at the same time, it is being tested on monkeys and it was discovered that the corona virus was eradicated from these animals in 28 days, even though they were infected with a large amount of germs.
The results of the initial phase of the vaccine are being hailed as encouraging, as the results of its trial in humans will be available for several months.
According to the New York Times, experiments on monkeys were carried out by American scientists at the Rocky Mountain Laboratory at the end of March.
For this purpose, six monkeys were given a vaccine developed by the Genes Institute and the Oxford Vaccine Group, and were subsequently exposed to a large number of corona viruses, which had previously infected other monkeys.
The monkeys in the study showed no signs of disease and were healthy 28 days later.
“This species of monkey is genetically very close to humans,” said Vincent Mونnster, head of the Rocky Mountain Laboratory’s Virus Ecology Unit.
The Jenner Institute is part of the Oxford Vaccine Group and the British government has pledged کروڑ 25 million for the university’s vaccine trial.
The trial on humans began on April 23 and is expected to end by September.
For the initial phase, 500 volunteers between the ages of 18 and 55 have been recruited.
The trial of 500 volunteers will continue till the middle of next month in which a total of 510 volunteers have been divided into 5 groups.
One of these groups will also receive a follow-up booster dose after using the vaccine for the first time.
Researcher Professor Sarah Gilbert said the technology used to develop the vaccine is already being used in 10 different treatments, but different test groups from different countries are needed for the corona virus. In order to ensure accurate results, this infection is spreading very fast in every corner of the world.
The research team is also seeking additional funding for large-scale vaccine development as it seeks mass production after a six-month human trial.
The idea is that the vaccine has proved effective for humans and will begin production in the fall, during which a final trial of 5,000 people will be completed and medical workers can start using it by September.
In fact, Oxford University is committed to developing one million doses of the vaccine by September.
It may seem impossible to develop a vaccine in such a short period of time, but the Oxford University team was already preparing for an epidemic like the corona virus.
To that end, they developed a genetically modified chimpanzee virus that is the basis of the new virus.
They hope to be able to make a safe virus part of a vaccine that could train the immune system to fight code 19.
The Oxford University vaccine is one of the few trials that has entered the human testing phase.
China is testing three different vaccines on humans, one of which has entered the second phase.
Similarly, in March in the United States, the Moderina company first started testing a vaccine on humans, while the trial of the vaccine of another company, Inouye, began earlier this month.
However, the vaccines are said to take one to one-and-a-half years to be developed and approved for use, but Chinese scientists are hopeful that the vaccine will be available to medical staff by September and the general public by next year. Will be able to use to prevent corona virus in the beginning.
In contrast, a research team from Oxford University claimed earlier this month that their vaccine would be ready by September.
Sarah Gilbert, a professor of vaccineology at Oxford University, told The Times of London that she was “80 per cent confident” that the vaccine developed by her team would work and be ready by September.
“No one can promise that this vaccine will work, but I am 80 percent confident that we will succeed,” he said.
Even if British scientists are able to develop and use the vaccine by September, experts say it will take several months to develop millions of doses of the vaccine.
Professor Sarah said talks were under way with the British government for funding and production would begin before the final results, which would give people immediate access to the vaccine.
“If all goes well, success is possible by the fall,” he said.